去势抵抗性前列腺癌晚期身体成分评估:聚焦肌肉减少症
本研究为单中心回顾性研究,纳入2005至2016年接受化疗内分泌治疗作为CRPC一线系统治疗的186例连续患者,化疗前用CT测定骨骼肌与脂肪指标,肌肉减少症定义为SMI<55 cm2/m2。154例(82.8%)符合肌肉减少症标准;低骨骼肌体积是肿瘤进展的独立不良预后因素,未发现身体成分参数与OS有统计学显著关联。
要点
- CRPC患者中肌肉减少症患病率高达82.8%(154/186)。
- 低骨骼肌体积是肿瘤进展的独立不良预后因素(HR 1.61,95%CI 1.10-2.35,p=0.02)。
- 未发现身体成分参数与OS有统计学显著关联,内脏脂肪比例高者OS有缩短趋势(p=0.06)。
核心结论
- 绝大多数CRPC男性患者存在肌肉减少症。
- 在本队列中,低骨骼肌体积是疾病进展的独立不良预后因素。
- 未检测到与OS有统计学显著关联的身体成分参数,但内脏脂肪比例高的患者OS有缩短趋势。
- 作者建议CT测定的身体成分参数可提供有用的客观预后因素,可能支持个体化治疗决策。
研究设计与样本
- 单中心回顾性研究。
- 评估2005至2016年间接受化疗内分泌治疗作为CRPC一线系统治疗的186例连续患者的数据。
- 化疗开始前使用计算机断层扫描(CT)数据测定骨骼肌与脂肪指数。
- 肌肉减少症定义为SMI<55 cm2/m2。
- 计算内脏与皮下脂肪比值及骨骼肌体积,采用Harrell一致性指数评估预测准确性。
主要发现
- 154例(82.8%)患者符合肌肉减少症标准。
- 139例(74.7%)完成至少六个周期多西他赛。
- 中位随访24.1个月内,年龄(HR 1.03,95%CI 1.01-1.06,p=0.02)、高PSA(HR 1.55,95%CI 1.07-2.25,p=0.02)和低骨骼肌体积(HR 1.61,95%CI 1.10-2.35,p=0.02)是肿瘤进展的独立预后因素。
- 随访期间93例(50%)患者死亡;化疗前存在肝转移(HR 1.32,95%CI 1.08-1.61,p<0.01)与更短OS相关。
- 内脏与皮下脂肪比值升高的患者OS有缩短趋势(p=0.06)。
关键数值与推荐
- 肌肉减少症定义:SMI<55 cm2/m2。
- 低骨骼肌体积对肿瘤进展:HR 1.61,95%CI 1.10-2.35,p=0.02。
- 年龄对肿瘤进展:HR 1.03,95%CI 1.01-1.06,p=0.02。
- 高PSA对肿瘤进展:HR 1.55,95%CI 1.07-2.25,p=0.02。
- 化疗前肝转移与OS:HR 1.32,95%CI 1.08-1.61,p<0.01。
临床怎么用
- 对CRPC患者可考虑利用化疗前CT数据评估身体成分,识别低骨骼肌体积的高进展风险患者。
- 身体成分参数可作为客观预后因素,辅助个体化治疗决策。
- 内脏脂肪比例高的患者可能需关注更短的OS趋势,但尚无统计学显著证据支持。
局限性
- 单中心回顾性研究设计。
- 未检测到与OS有统计学显著关联的身体成分参数,内脏脂肪比例与OS仅为趋势(p=0.06)。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To assess the prevalence of sarcopenia and whether body composition parameters are associated with disease progression and overall survival (OS) in castration-resistant prostate cancer (CRPC) patients. MATERIALS AND METHODS: This single-centre retrospective study evaluated data of 186 consecutive patients who underwent chemohormonal therapy between 2005 and 2016 as first-line systemic treatment for CRPC. Skeletal muscle and fat indices were determined using computerized tomography data before initiation of chemotherapy. Sarcopenia was defined as SMI of <55 cm2/m2. Visceral-to-subcutaneous fat ratio and skeletal muscle volume were calculated with body composition specific areas. Harrell's concordance index was used for predictive accuracy. RESULTS: A total of 154 (82.8%) patients met the criteria for sarcopenia; 139 (74.7%) individuals completed at least six cycles of docetaxel. Within a median follow-up of 24.1 months, age (HR 1.03, 95% CI 1.01-1.06, p = 0.02), high PSA (1.55, 95% CI 1.07-2.25, p = 0.02) and low skeletal muscle volume (HR 1.61, 95% CI 1.10-2.35, p = 0.02) were the only independent prognostic factor for tumor progression. Overall, 93 (50%) patients died during the follow-up period. The established prognosticator, the prechemotherapy presence of liver metastases (HR 1.32, 95% CI 1.08-1.61, p < 0.01) was associated with shorter OS. Moreover, we noted that patients with an elevated visceral-to-subcutaneous fat ratio tended to have a shorter OS (p = 0.06). CONCLUSION: The large majority of men with CRPC suffers from sarcopenia. In our cohort, low skeletal muscle volume was an independent adverse prognosticator for progression of disease. We could not detect a statistically significant body composition parameter for OS, although patients with a high proportion of visceral fat had a trend for shorter OS. However, we suggest that body composition parameters determined by CT data can provide useful objective prognostic factors that may support tailored treatment decision-making.
引用
- Stangl-Kremser J, Suarez-Ibarrola R, Andrea D, et al. Assessment of body composition in the advanced stage of castration-resistant prostate cancer: special focus on sarcopenia. Prostate Cancer Prostatic Dis. 2019. PMID: 31745255. doi:10.1038/s41391-019-0186-6
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。